Rat anti CD39 Ectonucleoside triphosphate diphosphohydrolase 1
| Code | Size | Price |
|---|
| MUB2012P | 0.1mg | £326.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rat
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: R22
Regulatory Status: RUO
Target Species: Human
Application: Flow Cytometry
Storage:
Store at 4°C or in small aliquots at -20°C.
Documents
Further Information
Applications Description:
The R22 antibody is suitable for the detection of human CD39 antigen by flow cytometry. Human spleen is suitable as a positive control.
Optimal antibody dilutions for the different applications should be determined by titration.
Optimal antibody dilutions for the different applications should be determined by titration.
Background:
CD39 is a transmembrane cell surface protein, which is a member of the ecto-nucleoside triphosphate diphosphohydrolase (ENTPDase) family. The CD39 molecule is primarily involved in the metabolism of purine nucleotides, converting extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate (AMP). In conjunction with CD73 (5? nucleotidase), CD39 plays a key role in regulating immunity and inflammation through the production of adenosine and purinergic signalling pathways. In addition, CD39 is reported to mediate B cell homotypic adhesion and inhibit ADP-induced platelet aggregation.
CD39 was originally identified on Epstein Barr virus transformed B cell lines and described as a B-cell activation marker. However, subsequent studies have shown that CD39 is also expressed on activated T-cells, T-regulatory cells, natural killer cells, tissue macrophages and endothelial cells. Increased expression of CD39 has also been reported in cases of chronic lymphocytic leukaemia and several solid tumours including colorectal and pancreatic cancer suggesting a potential role for CD39 in tumour development and progression.
CD39 was originally identified on Epstein Barr virus transformed B cell lines and described as a B-cell activation marker. However, subsequent studies have shown that CD39 is also expressed on activated T-cells, T-regulatory cells, natural killer cells, tissue macrophages and endothelial cells. Increased expression of CD39 has also been reported in cases of chronic lymphocytic leukaemia and several solid tumours including colorectal and pancreatic cancer suggesting a potential role for CD39 in tumour development and progression.
Caution:
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
Field of Interest:
CD Marker|Cancer|Immunology
Formulation:
Each vial contains 100?l 1mg/ml purified monoclonal antibody in phosphate buffered saline (PBS) containing 0.09% sodium azide.
Product:
Each vial contains 100?l 1mg/ml purified monoclonal antibody in phosphate buffered saline (PBS) containing 0.09% sodium azide.
Source:
R22 is a rat monoclonal IgG1 antibody derived by fusion of SP2/0 mouse myeloma cells with splenocytes from a WAG/Rij rat immunized with JY cells, a human B lymphoblastoid cell line.
Specificity:
The antibody R22 is directed against human CD39. The antibody has not been tested for cross reactivity with other species.
UniProt:
UniProt: P49961
References
1. Kansas GS, Wood GS, Tedder TF. (1991). Expression, distribution and biochemistry of CD39. J Immunol. 146:2235?2244.